ReviewMolecular diversity2026
Recent advances in piperazine derivatives as antibacterial agents: a comprehensive review (2020-2024).
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Computational structural dynamics and immunoinformatic analysis of EIEC IpaHMolecular diversity · 2026Article
- Design, synthesis and antitubercular evaluation of novel 5,6-diphenyl-1,2,4-triazine-piperazine derivatives targeting mycobacterial dihydrofolate reductase.ADMET & DMPK · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is a major global health challenge that requires the development of new therapeutic drugs. Piperazine, a privileged nitrogen-containing heterocyclic scaffold, has been identified as a viable framework for antibacterial drug development. This review examines current breakthroughs (2020-2024) in piperazine-based compounds with antibacterial activity. We discuss their structural modifications and potency against multidrug-resistant bacterial strains. Special importance is placed on newly synthesized compounds demonstrating high efficacy, as well as their structure-activity relationships (SAR). Additionally, we highlight ongoing challenges and future perspectives in the development of piperazine-based antibacterial agents, underscoring their potential to combat resistant pathogens.
Indexed as
Identifiers
40760217What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.